Tampere University

Tampere University (TAU, Tampereen korkeakoulusaatio sr) was created on 1 January 2019 as a merger of Tampere University of Technology (TUT) and University of Tampere (UTA).
Linkedin

Tampere University (TAU, Tampereen korkeakoulusaatio sr) was created on 1 January 2019 as a merger of Tampere University of Technology (TUT) and University of Tampere (UTA). The multidisciplinary, foundation-based Tampere University is Finland’s second-largest university with 20.000 students and 330 professors. TAU conducts scientific research in technology, health and society and provides the highest education within these fields.

In 2018, the total income of the two universities was 320 M€ of which 38 % was external research funding. TAU ranks fourth among all Finnish participants in H2020 funding. The university researcher community and support services have long experience on EU funding. TAU has an EU support team dealing with legal, financial and administrative issues. TAU has been awarded with the European Commission’s “HR Excellence in Research” logo.

In the project, TAU is represented by the Faculty of Medicine and Health Technology (MET) which employs ~80 Principal Investigators and ~700 persons in biomedical engineering, cell and molecular biology and clinical medicine. The MET gathers multidisciplinary research in medicine, life sciences and medical technology to create new knowledge and commercial solutions by combining the engineering and biology efficiently with the modern medicine.

Interest and Role in the Project

The main focus will lie in developing an engineered model of human epileptic brain and microfabricated porous membrane for encapsulation of the biocomputing cells.

The Faculty of Medicine and Health Technology (MET) at Tampere University will support the project by providing its expertise on microfabrication, membrane technology, surface modification and organ- on-chip models. The main focus will lie in developing an engineered model of human epileptic brain and microfabricated porous membrane for encapsulation of the biocomputing cells. The project has strong synergy with the research agenda of the group which includes development of brain-on-chip systems for brains diseases and injuries including stroke and epilepsy. The project allows the team to apply and further develop its fabrication skills towards in vivo applications of its core technology.